BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 37204722)

  • 1. An Overview of Heparin Monitoring with the Anti-Xa Assay.
    Dean CL
    Methods Mol Biol; 2023; 2663():343-353. PubMed ID: 37204722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The PiCT
    Brisset AC; Ferrández A; Krause M; Rathbun S; Marlar R; Korte W
    J Thromb Haemost; 2016 Nov; 14(11):2187-2193. PubMed ID: 27582411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of red blood cell transfusion utilization between anti-activated factor X and activated partial thromboplastin monitoring in patients receiving unfractionated heparin.
    Belk KW; Laposata M; Craver C
    J Thromb Haemost; 2016 Nov; 14(11):2148-2157. PubMed ID: 27543785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion.
    Guervil DJ; Rosenberg AF; Winterstein AG; Harris NS; Johns TE; Zumberg MS
    Ann Pharmacother; 2011 Jul; 45(7-8):861-8. PubMed ID: 21712506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of a Calculation-Free Weight-Based Unfractionated Heparin Nomogram With Anti-Xa Level Monitoring Compared With Activated Partial Thromboplastin Time.
    Kindelin NM; Anthes AM; Providence SM; Zhao X; Aspinall SL
    Ann Pharmacother; 2021 May; 55(5):575-583. PubMed ID: 32964730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Agreement between activated partial thromboplastin time and anti-Xa activity in critically ill patients receiving therapeutic unfractionated heparin.
    Ratano D; Alberio L; Delodder F; Faouzi M; Berger MM
    Thromb Res; 2019 Mar; 175():53-58. PubMed ID: 30708169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticoagulation Monitoring with Activated Partial ThromboPlastin Time and Anti-Xa Activity in Intensive Care Unit Patients: Interest of Thrombin Generation Assay.
    Billoir P; Elie T; Levy JH; Besnier E; Dureuil B; Veber B; Le Cam-Duchez V; Clavier T
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antifactor Xa levels vs. activated partial thromboplastin time for monitoring unfractionated heparin. A pilot study.
    Samuel S; Allison TA; Sharaf S; Yau G; Ranjbar G; Mckaig N; Nguyen A; Escobar M; Choi HA
    J Clin Pharm Ther; 2016 Oct; 41(5):499-502. PubMed ID: 27381025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heparin dosage, level, and resistance in SARS-CoV2 infected patients in intensive care unit.
    Novelli C; Borotto E; Beverina I; Punzi V; Radrizzani D; Brando B
    Int J Lab Hematol; 2021 Dec; 43(6):1284-1290. PubMed ID: 33855802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative trial of anti-factor Xa levels versus the activated partial thromboplastin time for heparin monitoring.
    Vandiver JW; Vondracek TG
    Hosp Pract (1995); 2013 Apr; 41(2):16-24. PubMed ID: 23545756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Hirsh J; Raschke R
    Chest; 2004 Sep; 126(3 Suppl):188S-203S. PubMed ID: 15383472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of anti-Xa assay in monitoring unfractionated heparin therapy in contemporary antithrombotic management.
    Safani M; Appleby S; Chiu R; Favaloro EJ; Ferro ET; Johannes J; Sheth M
    Expert Rev Hematol; 2023 Jan; 16(1):1-8. PubMed ID: 36637400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activated partial thromboplastin time and anti-xa measurements in heparin monitoring: biochemical basis for discordance.
    Takemoto CM; Streiff MB; Shermock KM; Kraus PS; Chen J; Jani J; Kickler T
    Am J Clin Pathol; 2013 Apr; 139(4):450-6. PubMed ID: 23525615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic monitoring of unfractionated heparin - trials and tribulations.
    Baluwala I; Favaloro EJ; Pasalic L
    Expert Rev Hematol; 2017 Jul; 10(7):595-605. PubMed ID: 28632418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concordance between Activated Partial Thromboplastin Time and Antifactor Xa Assay for Monitoring Unfractionated Heparin in Hospitalized Hyperbilirubinemic Patients.
    Mahmoud L; Zullo AR; McKaig D; Berard-Collins CM
    R I Med J (2013); 2016 Mar; 99(3):33-7. PubMed ID: 26929970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin.
    Vandiver JW; Vondracek TG
    Pharmacotherapy; 2012 Jun; 32(6):546-58. PubMed ID: 22531940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Managing Factor Xa Inhibitor to Unfractionated Heparin Transitions by aPTT Versus a Treatment Guideline Utilizing Heparin Anti-Xa Levels.
    Dingus SJ; Smith AR; Dager WE; Zochert S; Nothdurft SA; Gulseth MP
    Ann Pharmacother; 2022 Dec; 56(12):1289-1298. PubMed ID: 35499336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring of heparin therapy beyond the anti-Xa activity assay: Evaluation of a thrombin generation assay.
    Vermeiren P; Vandevelde A; Peperstraete H; Devreese KMJ
    Int J Lab Hematol; 2022 Aug; 44(4):785-795. PubMed ID: 35438827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of correlation between heparin dose and standard clinical monitoring tests in treatment with unfractionated heparin in critically ill children.
    Kuhle S; Eulmesekian P; Kavanagh B; Massicotte P; Vegh P; Lau A; Mitchell LG
    Haematologica; 2007 Apr; 92(4):554-7. PubMed ID: 17488668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. APTT therapeutic range for monitoring unfractionated heparin therapy. Significant impact of the anti-Xa reagent used for correlation.
    Toulon P; Smahi M; De Pooter N
    J Thromb Haemost; 2021 Aug; 19(8):2002-2006. PubMed ID: 33555096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.